HomeIndustryIt's not the ...

It’s not the right time to quit: Intra-Cellular Therapies Inc. (ITCI) Stock

Goldman lowered the price target for the Intra-Cellular Therapies Inc. (NASDAQ:ITCI) stock from “a Buy” to “a Neutral”. The rating was released on August 22, 2022, according to finviz. The research report from UBS has initiated the stock to Buy, with a price target set at $75. The stock was initiated by Piper Sandler, who disclosed in a research note on April 22, 2022, to Neutral and set the price objective to $59. In their research brief published February 16, 2022, Goldman analysts initiated the Intra-Cellular Therapies Inc. stock to Buy with a price target of $64.

The latest trade, Performances and Moving Averages give us the following Picture

The share price of Intra-Cellular Therapies Inc. (NASDAQ:ITCI) raised 1.64% to close Friday’s market session at $45.99, higher as compared to yesterday’s close. The stock price fluctuated between $43.90 and $46.45 throughout the trading session with the volume trading being 961530 shares, which represented a significant variation when compared to the three months average volume of 672.15K shares. The firm’s stock price fluctuated 4.52% within the last five trades and -8.02% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price decreased -8.98% in the last 6 months and -12.85% was subtracted to its value over the previous 3 months. ITCI stock is trading at a margin of -1.60%, -4.14% and -9.67% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".


As of the close of trading, ITCI deals in the Healthcare domain. The stock is trading -30.32 percent below its 52-week high and 9.47 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -27.12. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.

What Does Intra-Cellular Therapies Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?

The stock’s market cap achieved a total value of $4.41 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 17.60 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 6.65, which equates the market value of a stock with its book value.

Is Insider Trading a Real Thing?

Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 0.10 percent of Intra-Cellular Therapies Inc. shares are owned by insiders, and 94.50 percent are held by financial institutions. Mates Sharon, the Chairman, President & CEO at Intra-Cellular Therapies Inc. (ITCI) has sold 20,565 shares of firm on Mar 13 at a price of $44.99 against the total amount of $0.93 million. In another inside trade, Durgam Suresh K., EVP, Chief Medical Officer of Intra-Cellular Therapies Inc. (NASDAQ:ITCI) sold 7,344 shares of the firm on Mar 13 for a total worth of $0.33 million at a price of $45.04. An inside trade which took place on Mar 13, EVP and General Counsel of Intra-Cellular Therapies Inc. Halstead Michael sold 7,344 shares of firm against total price of $0.33 million at the cost of $44.94 per share.



Please enter your comment!
Please enter your name here

Recent Post